Upgrade to SI Premium - Free Trial

Ipsen acquires Memo Therapeutics, adding kidney transplant drug

July 22, 2026 1:00 AM
Ipsen (Euronext: IPN; ADR: IPSEY) has completed its acquisition of Memo Therapeutics AG, a late-stage biotech company developing potravitug, a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

FDA Mergers and Acquisitions